Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Kinan Attassi

Infectious Disease Munster, IN Medical Doctor

NPI 1255428157 CMS profile 283487

740 Seberger Dr, Northwest Indiana Id Associates Pc, Munster, IN 46321

Open in the dashboard

General payments

$240

12 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Kinan Attassi of Munster, IN is reported in the CMS Open Payments database as having received $240 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 40th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $27 1
2022 General $36 2
2020 General $79 4
2019 General $98 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kinan Attassi
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Kinan Attassi were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Kinan Attassi Infectious Disease median Middle half National median
2019 $98 $190 $60–$862 $163
2020 $79 $124 $32–$606 $114
2021 $0 $148 $38–$905 $132
2022 $36 $166 $50–$834 $149
2023 $27 $171 $57–$787 $160
2024 $0 $176 $52–$752 $164
2025 $0 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Smith+Nephew, Inc. $51 3 payments
  2. Gilead Sciences, Inc. $47 2 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $42 2 payments
  4. Chiesi USA, Inc. $37 2 payments
  5. AbbVie, Inc. $27 1 payment
  6. ConvaTec Inc. $19 1 payment
  7. ADMA BioManufacturing LLC $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $240 12 payments
Products named General payments · program years 2019–2023
  1. Santyl $51 3 payments
  2. XIFAXAN $42 2 payments
  3. KENGREAL 50MG/10ML L $37 2 payments
  4. CLEVIPREX 50MG/100ML $37 2 payments
  5. AVYCAZ $27 1 payment
  6. TEFLARO $27 1 payment
  7. CONVATEC INC. $19 1 payment
  8. AQUACEL AG+ $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

648

Median for Infectious Disease: 268

Drug cost

$334,663

Median for Infectious Disease: $217,595

Branded share of claims

38.7%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 30 $115,165
Daptomycin Generic 42 $72,602
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 14 $67,083
Isentress Raltegravir Potassium Brand 12 $27,688
Ertapenem Ertapenem Sodium Brand 23 $18,720
Carbidopa Generic 23 $11,957
Vancomycin Hcl Generic 24 $7,032
Cefuroxime Cefuroxime Axetil Brand 105 $2,816
Linezolid Generic 31 $2,584
Cefepime Hcl Generic 16 $2,361

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$265,769

Medicare's payments for the services billed

Medicare patients

521

Average age 74

Services billed

3,734

274 women, 247 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Diabetes 64%
Ischemic heart disease 60%
Chronic kidney disease 59%
Heart failure 56%
COPD 44%
Atrial fibrillation 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record